Arrayit Corporation Aces Three Consecutive Rounds of Proficiency Testing with the College of American Pathologists
October 08 2018 - 5:30AM
Sunnyvale, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation
(OTC: ARYC), a life sciences and personalized medicine
company, reports that its clinical team aced three consecutive
rounds of blinded-specimen Proficiency Testing (PT) with the
College of American Pathologists (CAP). The SC-2017, SA-2018
and SB-2018 triannual CAP Diagnostic Immunology Surveys require
highly quantitative measurements of immunoglobulin E (IgE), the
antibody molecules measured by the company’s finger stick allergy
microarray tests. Arrayit’s highly accurate PT performance
showcases the robustness of the company’s proprietary allergy
testing platform and reagents, which are increasingly being
leveraged by doctors as a tool to diagnose and treat allergy
and asthma.
Arrayit recently completed an allergy testing pilot program for
a top retail chain, established a nationwide network of 1,700
allergy sales professionals, met with top officials at the United
States Food and Drug Administration (FDA) regarding approval of a
major product line, signed allergy testing contracts with a
consortium of 178 medical clinics, received approval for in-store
promotions by a major retailer, announced allergy testing
partnerships with major allergy therapeutics providers, received
approval for direct Medicare billing by the Centers for Medicare
and Medicaid Services (CMS), and reported the sale and shipment of
clinical instrumentation to the FDA. Consistent high-level
proficiency testing performance, supervised by the rigorous and
impartial CAP, facilitates reimbursement by private and government
allergy test payors.
Chief Executive Officer Rene Schena states, “Proficiency testing
excellence by the clinical personnel in our California-based
Clinical Laboratory Improvement Amendments (CLIA) laboratory
illustrates our commitment to providing the most accurate and
valuable healthcare information to doctors for their
patients. Our value-based medicine approach, coupled with
rapid and non-invasive allergy testing technology, has
transformative implications for the health and wellness
marketplaces.”
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads
and empowers the research, biotechnology, pharmaceutical, clinical
and healthcare sectors through the discovery, development and
manufacture of proprietary life science and personalized medicine
products and services to advance biomedical research and improve
wellness and human health. Please
visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such
as "expect", "believe", and "should". Although we believe our
expectations are reasonable, our operations involve a number of
risks and uncertainties that are beyond our control, and these
statements may turn out not to be true. Risk factors associated
with our business, including some of the facts set forth herein,
are detailed in the Company's public filings.
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Nov 2023 to Nov 2024
